The annual meeting of the American Diabetes Association set the stage for new data backing experimental drugs for the disease. Merck presented several studies that supported Januvia for Type 2 diabetes, with data that showed the drug lowered blood sugar without triggering significant side effects. Januvia is a DPP-4 inhibitor and its approval would mark a new class of drugs for diabetes. Pfizer also presented data for its inhaled form of insulin, Exubera. And Novartis is expected to make a presentation on Galvus. The FDA is expected to make a decision on Januvia by the end of the year, with a decision on Galvus coming in early 2007.
- read the article on the data from the Wall Street Journal (sub. req.)
PLUS: The number of people suffering from diabetes globally has jumped from 30 million to 230 million in the last 20 years. Article
ALSO: Novo Nordisk is touting new data for its diabetes drug Levemir. Report